ASH Poster Walks

ASH Poster Walk on Hemostasis and Thrombosis: from Basic Concepts to Clinical Applications Hosted by Blood Vessels, Thrombosis & Hemostasis (For In-person Participants)

Over the years, discoveries and innovations in the Hemostasis and Thrombosis field have fueled the development of several new generations of therapeutics. This proposed Poster Walk will feature Hemostasis and Thrombosis research with a specific focus on discoveries of fundamental mechanisms that could form the basis for novel therapies and (pre)clinical studies in which innovative therapies are developed and evaluated. 

This walk will highlight the current state-of-the-art specifically focusing on abstracts that feature inventive and groundbreaking research in bleeding disorders, thrombosis, platelet disorders, and associated therapies. The walk aims to inspire (a future generation of) Hemostasis and Thrombosis researchers. 

Join us in the Blood Studio located in the main Poster Hall for this in-person poster walk hosted by ASH’s Blood Vessels, Thrombosis & Hemostasis journal.

Organizer:

Mettine H.A. Bos, PhD
Leiden University Medical Center
Leiden, Netherlands

Speakers:

Huiying Zhi, MD, PhD
Versiti
Milwaukee, WI
Prophylactic Administration of HPA-1a–Specific Antibody RLYB212 Safely Prevents Fetal/Neonatal Alloimmune Thrombocytopenia in Pregnant Mice

Stephan Peters, PhD
Alveron Pharma
Oss, Netherlands
First in-Human Study with Okl-1111, a Novel Small Molecule Universal Anticoagulant and Platelet Inhibitor Reversal Agent

Maya Mardini
University of Kentucky
Lexington, KY
Small Molecule Compounds for Heparin Reversal and Their Use in Heparin Quantitation

Molly Brakhane, MSc
Washington University School of Medicine
Saint Louis, MO
Altered Calcium Signaling Via STIM1 Drives Aberrant Megakaryopoiesis and Myelofibrosis

José Diogo Oliveira, PhD
University of Campinas (UNICAMP)
Campinas, LA, Brazil
Association between Extracellular Vesicles (EVs) and Thrombosis in Antiphospholipid Syndrome

Surabhi Rao
Sonothera Inc
San Francisco, CA
Targeted Non-Viral Gene Delivery through Transcutaneous Ultrasound Enables Robust, Redosable, Titratable, and Durable FVIII and FIX Gene Expression in the Liver in Murine Models

ASH Poster Walk on Deciphering the Hematopoietic Stem Cell Niche: From Normal Function to Malignancy Hosted by Blood Neoplasia (For In-person Participants)

Hematopoietic stem cells (HSCs) are pivotal in the production and lineage determination of blood cells, maintained by an intricate network of interactions within the bone marrow (BM) niche. Disruption of this tightly regulated environment leads to hematopoietic deregulation and the development of hematological malignancies. Recent advances in both in vitro and in vivo techniques have paved the way for innovative diagnostic and therapeutic strategies targeting hematological malignancies within their microenvironment.

The Poster Walk will showcase the latest high-impact research (featured in the posters) on the HSC niche, highlighting both basic research and clinical implications. It will provide a valuable platform for the exchange of knowledge and ideas, promoting greater understanding and collaboration within the ASH community as well as raising awareness and stimulate interest in this often under-represented but crucial area of hematology.

Join us in the Blood Studio located in the main Poster Hall for this in-person poster walk hosted by ASH’s Blood Neoplasia journal.

Organizer:

Manja Wobus
University Hospital Dresden, TU Dresden
Dresden, Germany

Speakers:

Anna Navarro Figueredo
Technical University of Munich (TUM), School of Medicine and Health
Munich, Germany
Single-Cell Transcriptomics of Bone Marrow Mesenchymal Stromal Cells Identifies Altered CLCF1 Signaling in DNMT3A-Mutated Clonal Hematopoiesis

Ebubechukwu Osinachi Nwarunma, MSc,BSc
Glasgow Caledonian University
Glasgow, SCO, United Kingdom
M2-like Macrophages Transfer Mitochondria to Acute Myeloid Leukaemia Cells Via Tunnelling Nanotubes Promoting Therapy Resistance

Manuela Albuquerque De Melo, MSc
University of São Paulo at Ribeirão Peto Medical School
Ribeirão Preto, Brazil
Molecular Mechanisms Associated with Autophagy Inhibition to Overcome Resistance to FLT3 Inhibitors

Stefania Leone
University federico II of Naples
Naples, Italy
A Study on the Effect of Luspatercept on Regulatory T Cells and Myeloid Derived Suppressor Cells in Low Risk Myelodysplastic Syndrome with Ring Sideroblasts

Kim Uyen Cong Nguyen, MSc
University of Mississippi Medical Center
Jackson, MS
Resolution of Inflammation Increases Hematopoietic Stem Cell Number and Erythropoiesis

Christina M Kaszuba, MS
University of Rochester
Dansville, NY
Temporal Single Cell Analysis of Myeloid Leukemia Microenvironment

ASH Poster Walk on What's New in Complement-Related Diseases? Hosted by Blood Red Cells & Iron (For In-person Participants)

Complement-related diseases in relevance to the hematologist traditionally include paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Nevertheless, novel developments have implicated complement activation in a number of disorders that are relevant to hematologists, including hematopoietic stem cell transplantation thrombotic microangiopathy (HSCT-TMA), delayed hemolytic transfusion reaction (DHTR) and other complications of sickle cell disease, antiphospholipid antibody syndrome, and HELLP syndrome. 

This Poster Walk will feature abstracts on complement activation and inhibition and foster collaborations amongst researchers and physicians looking to identify novel inhibitors and therapeutics in this area. 

Join us in the Blood Studio located in the main Poster Hall for this in-person poster walk hosted by ASH’s Blood Red Cells & Iron journal.

Organizer:

Eleni Gavriilaki, MD,PhD
Aristotle University of Thessaloniki
Thessaloniki, Greece

Speakers:

Alexander Röth, MD
University Hospital Essen, University Duisburg-Essen
Essen, Germany
Iptacopan Monotherapy in Patients with Cold Agglutinin Disease: Phase II Study Results

Michelle L Schoettler, MD
Emory University, Children’s Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center
Atlanta, GA
Terminal Complement Activation in Children with Sinusoidal Obstructive Syndrome after Hematopoietic Cell Transplantation

Bruno Fattizzo, MD
Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milano, Italy
Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results

Michael Daunov, DO
University Hospitals Seidman Cancer Center
Cleveland, OH
A Retrospective Study of C5b-9 and MASP2 Deposition in Skin Microvasculature As a Prognostic and Diagnostic Tool for Transplant-Associated Thrombotic Microangiopathy

Moritz Saxenhofer, PhD
CSL Behring
Bern, AL, Switzerland
Transcriptomic Profiling Supports the Phenotypic Classification of Stable-State Sickle Cell Disease Patients

Maria Queralt Salas, MD
Hospital Clinic de Barcelona, ICAMS
Barcelona, Spain
Frailty Syndrome Is Associated with Increased Endothelial Activation and Post-Transplant Complications in Allo-HCT Patients

ASH Poster Walk on Blood Immunology & Cellular Therapy: Advancing Innovations and Translational Insights Hosted by Blood Immunology & Cellular Therapy (For In-person Participants)

Cellular therapies have revolutionized the treatment landscape of blood disorders, offering novel approaches in immunotherapy and transplantation. This poster walk will provide a crucial platform to discuss cutting-edge research and developments in this area. Focused on themes such as experimental transplantation, adoptive immunotherapy, and clinical outcomes in both allogeneic and autologous settings, this walk will showcase the most exciting findings in the posters featured in this year’s Annual Meeting.

Participants can expect to delve into topics ranging from basic biology and pre-clinical models to acute transplant toxicities and immune reconstitution. By featuring presentations on conditioning regimens, graft-versus-host disease (GVHD), and disease recurrence, the event aims to foster deep insights and collaboration among researchers, clinicians, and industry professionals. Attendees will gain valuable perspectives on current challenges and future directions in cellular therapy and immunodiagnostics, enhancing their ability to translate research discoveries into clinical practice.

Join us in the Blood Studio located in the main Poster Hall for this in-person poster walk hosted by ASH’s Blood Immunology & Cellular Therapy journal.

Organizer:

Samer Al Hadidi, MD,MSc
University of Arkansas for Medical Sciences
Little Rock, AR

Speakers:

Milos D Miljkovic, MD,MSc
Cartesian Therapeutics
Frederick, MD
Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease

Nikki Agarwal, MD
University Hospitals Seidman Cancer Center
Cleveland, OH
A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation

Evandro Bezerra, MD
The Ohio State University
Columbus, OH
Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies

Maria Lia Palomba, MD
Memorial Sloan Kettering Cancer Center
New York, NY
A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)

Lev Gorfinkel, MD
Boston Children's Hospital
Boston, MA
Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2’)

Fabian Mueller, MD
University Hospital Erlangen
Erlangen, Germany
Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies

ASH Poster Walk on Improving Access to Cell and Gene Therapies Hosted by Blood Global Hematology (For In-person Participants)

Novel cell and gene therapies have transformed the care of patients with hematologic disorders. Unfortunately, these life-saving therapies are not accessible to all patients who may benefit from them, both on a local and global scale.

This Poster Walk is meant to raise awareness about the challenges (both locally and internationally) of delivering cell and gene therapies to patients, highlight important research addressing these issues, and enhance discussions related to these topics. To that end the walk will highlight abstracts focusing on national and international disparities in access to cell and gene therapies, as well as abstracts highlighting how to make these therapies more accessible for patients (reducing cost, improving infrastructure, etc.).

Join us in the Blood Studio located in the main Poster Hall for this in-person poster walk hosted by ASH’s Blood Global Hematology journal.

Organizer:

Natalie Grover, MD
University of North Carolina
Chapel Hill, NC

Speakers:

Veit L. Buecklein, MD
LMU University Hospital
Munich, Germany
Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany

Brian Hoeynck, MD
Vanderbilt University Medical Center
Nashville, TN
Impact of Patient Distance from Center on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma

Marie Michele Sainvil, MD
Duke University School of Medicine
Durham, NC
Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Brid M Ryan, PhD MPH
MiNA Therapeutics
London, United Kingdom
Small Activating RNA-Mediated Induction of HBG Via Liposome Delivery for In Vivo Treatment of Sickle Cell Disease and Beta-Thalassemia

Z. Jane Wang, PhD
Tessera Therapeutics
Somerville, MA
Delivery of Gene Writers In Vivo to Hematopoietic Stem Cells and T Cells Using Targeted and Untargeted Lipid Nanoparticles (LNP)

Roy Khalife, MD,FRCPC
Ottawa Hospital Research Institute
Ottawa, ON, Canada
From Theory to Therapy: Evaluating Canadian Hemophilia Treatment Centres' Readiness for Gene Therapy Implementation

ASH Poster Walk on Hello, World! A Walk Through The Artificial Intelligence Network

With the growing use of artificial intelligence (AI) and machine learning in research and healthcare, and the growing number of AI related abstracts submitted to the ASH Annual Meeting, there is increasing interest in learning about this field.

This Poster Walk will feature abstracts highlighting the application of AI in hematology science, discussing the topic at an elementary level and highlight some of the key contributions.

Join us for this virtual Poster Walk session.

Organizer:

Barbara D Lam, MD
Beth Israel Deaconess Medical Center
Boston, MA

Speakers:

Lydian A. De Ligt, MD
Amsterdam University Medical Centers
Amsterdam, AL, Netherlands
Artificial-Intelligence Driven Quantification of Sickle Red Blood Cell Morphology As an Objective Disease Marker

Saverio D'Amico, MSc
IRCCS Humanitas Research Hospital
Rozzano, Milan, Italy
An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

Ramy El-Assal, B.S. in Neuroscience
The Ohio State University
Columbus, 
ASH-G Bot: An Artificial Intelligent Chatbot Trained on the American Society of Hematology (ASH) Guidelines

Shruti Sridhar
Cancer Science Institute of Singapore, National University of Singapore
Singapore, Singapore
Machine Learning Classification of Spatial Patterns of Malignant Cells Reveals Implications in Prognosis and Tumor Microenvironment Composition in Lymphoma

Robert L. Davis, MD
University of Tennessee Health Science Center
Memphis, TN
Towards Remote Monitoring of Sickle Cell Disease for Heart Failure: A Single Lead ECG-AI Model

Meihua Long, PhD candidate
Peking University
Beijing, China
Time Series Deep Neural Network Identifies Lymphoma Patients Suitable for CAR-T Cell Therapy Using EHR Data

ASH Poster Walk on Health Equity in Hematology

This Poster Walk will highlight works that investigate structural barriers impacting provision of care across hematology for patients from underserved racial/ ethnic groups, those of lower socio-economic status, and other vulnerable groups. In particular, the walk will spotlight research (featured in the posters) that advances efforts to diversify patient populations, mitigate barriers to care, and maximize the equitable provision of optimal care for patients from vulnerable populations. The walk will also feature posters outlining work being done to make our field more inclusive for patients, donors, and caregivers, as well as for practitioners across the hematology workforce. It will serve to connect stakeholders in health equity in hematology and facilitate discussions on the state of health equity research in the field.

Join us for this virtual Poster Walk session.

Organizer:

Warren B Fingrut, MD,MPH
The University of Texas MD Anderson Cancer Center
Houston, TX

Speakers:

Fartoon M Siad, MD, MSc
University of Toronto
Toronto, ON, Canada
"There Is so Much Power in Just Believing Someone": Understanding the Lived Experiences of Women with Heavy Vaginal Blood Loss

Kishan A Bhatt, MPA
Columbia University Vagelos College of Physicians and Surgeons
New York, NY
Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma

Sara Suhl, BS
Columbia University Vagelos College of Physicians and Surgeons
New York City, NY
Health Disparities in Lived Experiences of Patients with Cutaneous T-Cell Lymphoma: An All of Us Database Analysis

Lauren E. Merz, MD,MSc
Mass General Brigham
Boston, MA
Assessing the Contribution of Duffy Null Phenotype to Disparities in Eligibility Criteria for Clinical Trials for Newly-Diagnosed Colorectal Cancer

Christopher T. Su, MD,MPH
Fred Hutchinson Cancer Center
Seattle, WA
Associations of Long-Term Financial Hardship with Autologous Transplant and Overall Survival in Patients with Multiple Myeloma

Srishti Sareen, MD
VA Medical Center
Memphis, TN
Routine Screening of African American Males in Hematology Oncology Clinic for G6PD Deficiency: A Prospective Comparative Study of a Pharmacogenomic Panel Versus Standard Enzyme Assay